Wilson Therapeutics AB announced the appointment of Hans Schikan to its board of directors last week.
"We are delighted to welcome Hans to Wilson's board of directors," CEO Jonas Hansson said. "Hans brings significant global biopharmaceutical industry experience to Wilson, and we look forward to his contributions to the company."
Schikan was trained as a pharmacist at Utrecht University in the Netherlands. Most recently, he was the CEO of Prosensa, an RNA-modulating company developing novel therapies for rare neuromuscular and neurodegenerative disorders.
Schikan is a board member of SOBI, Hansa Medical and of the Dutch Top Sector Life Sciences & Health. He was previously a member of the Biotechnology Industry Organization's Emerging Companies Section Governing Board and is past chairman of Nefarma, the industry association for the Dutch branches of innovative pharmaceutical companies. Before his time at Prosensa, he held various senior management positions at Organon and Genzyme.
“I am delighted to join Wilson during such an exciting time in the company's development," Schikan said. "I look forward to leveraging my experience developing innovative products to help Wilson make a difference in the lives of people with rare diseases."
Company shareholders approved Schikan's appointment during the Annual General Meeting on June 30.